STATS Flashcards
Appendicitis in Pregnancy
1:1500
Vasectomy
1: 2000
Female sterilisation
1: 200
hysteroscopic - 2: 1000
Heterotopic pregnancy
1: 30000
8: 1000 with ART
Maternal Cardiac arrest
1: 12500 / 1: 30000
Coil Expulsion
1: 20
Coil Perforation
1-2: 1000
Increased risk by 6-8 times if between 48 hours or 6 weeks following pregnancy
Female condom failure
22%
Male 18%
Rate of twin pregnancies
3%
Note maternal mortality is 2.5 higher than general population
Turners Syndrome
1: 2500 - 1: 3000
Stress Urinary Incontinence
1: 3
Pelvic floor prolapse
1: 9
Combined test detection rate
90%
Reversion to breech following ECV
3%
Risk of shoulder dystocia
<1% (0.58 - 0.7%)
If previous then x 10 higher
Risk of shoulder dystocia after 1 previous
<1% (0.58 - 0.7%)
If previous then x 10 higher
Risk of endometrial hyperplasia with granulosa cell tumour
40% risk of EH
10-15% risk of endometrial cancer
Risk of endometrial cancer with granulosa cell tumour
40% risk of hyperplasia
10-15% risk of endometrial cancer
Risk of uterine rupture
1: 200 - 0.5% or 0.2-0.7%
if labour augmentation risk 2-3x higher
Risk of repeat LSCS with VBAC
1: 4
Fetal laceration at LSCS
2%
Risk of OASIS
2.9%
6.1% - Primip
1.7% - multip
Recurrence 5-7%
5% with VBAC
60-80% asymptomatic at 12 months
Risk of OASIS in multip
2.9%
6.1% - Primip
1.7% - multip
Recurrence 5-7%
5% with VBAC
60-80% asymptomatic at 12 months
Risk of OASIS in primp
2.9%
6.1% - Primip
1.7% - multip
Recurrence 5-7%
5% with VBAC
60-80% asymptomatic at 12 months
Risk of OASIS after previous
2.9%
6.1% - Primip
1.7% - multip
Recurrence 5-7%
5% with VBAC
60-80% asymptomatic at 12 months
Post-partum Psychosis
1-2: 1000
Post-partum psychosis in bipolar
1: 4
Risk of twins delivering before 37 weeks
60%
Risk of triplets delivering before 35
75%
Rate of MCDA
30% OF TWINS
Rate of MCMA
1% of twins
Uterine perforation in EVAC
1: 1000
VBAC success rate
72-75%
Px VD 85-90%
Risk of repeat ectopic
18.5%
Mitochondrial disorders
1: 5000 - 1: 8000
GBS positive risk of neonatal transmission
1: 400 ( 2-3: 1000)
If GBS positive previous pregnancy and not tested in current pregnancy risk is 1:800
Risk of cord prolapse
0.1 - 0.6%
Diabetes Insipidus
2-4 : 100, 000
Laproscopic abdominal cerclage risk of conversion to open
10%
> 85% successful pregnancy rate
Primary herpes infection neonatal infection risk
41%
Recurrent Herpes risk of neonatal infection
0-3%
Placenta praevia after 1 LSCS
1 LSCS 1%
2 LSCS 1.7%
3 LSCS 2.8%
4-8 / 1000 - praevia / accreta
Placenta praevia after 2 LSCS
1 LSCS 1%
2 LSCS 1.7%
3 LSCS 2.8%
Placenta praevia after 3 LSCS
1 LSCS 1%
2 LSCS 1.7%
3 LSCS 2.8%
VERTEX
SUBOCIPITO-BREGMATIC 9.5cm
FACE
SUBMENTO-BREGMATIC 9.5cm
OP
OCCIPTIO-FRONTAL 11.5cm
BROW
MENTO-VERTICAL 13cm
Risk of chorioamnionitis following amniocentesis
1: 1000
Miscarriage risk 1%
Risk of miscarriage following amniocentesis
Miscarriage risk 1%
Complications in planned LSCS
16 : 100
24: 100 in LSCS performed in labour
33: LSCS at 9-10cm dilated
Complications in LSCS performed in labour
24: 100
33: LSCS at 9-10cm dilated
16: 100 in planned LSCS
Emergency hysterectomy in LSCS
7-8: 1000
11: 100 with placenta praevia
Bladder injury at LSCS
1: 1000
Ureteric injury at LSCS
1: 10000
Death at LSCS
1: 12,000
Risk of haemorrhage at LSCS
5: 1000
Risk of infection at LSCS
6: 100
Emergency hysterectomy with placenta praevia
11: 100
27: 100 if previous section
VTE in placenta praevia at LSCS
3: 100
Bladder injury / ureteric at LSCS in plaenta praevia
6: 100
Future placenta praevia
23: 1000
Massive obstetric haemorrhage with placenta praevia
21: 100
Very common
1: 1 - 1: 10 (family member)
Common
1:10 - 1: 100 ( person in street)
Uncommon
1: 100 - 1: 1000 ( person in village)
Rare
1: 1000 - 1: 10000 ( person in small town)
Very rare
< 1: 10,000 ( person in large town)
Risk of serious injury at diagnostic lap
2: 1000
15% of bowel injuries may not be noticed at time of procedure
Risk of adhesions under the umbilicus following low transverse incision
23%
50 - with midline
Risk of adhesions under the umbilicus following midline laparotomy
50%
23% with low transverse
Percentage of bowel injuries not recognised at time of laparosopy
15%
Percentage of women who could die during laparsocop
3-8: 100 000
Percentage of women under MTX for ectopic requiring surgery
10%
OASIS with vacuum
1-4: 100
1: 10 - vulval tear
8-12: 100 - forceps
1: 5 - vulval tear
OASIS with foceps
8-12: 100
1: 5 - vulval tear
1-4: 100 - vacuum
1: 10 - vulval tear
Cephalohaematoma
Bleed limited to periostium
Does not cross suture lines
1-12 : 100
Subgaleal haematoma
Most serious Crosses suture lines Between periostium and aponeurosis Puffy eyelids 3-6 : 100
Common risks with 3/4th tear
faecal urgency 26: 100
Perineal pain 9: 100
Wound Infection 8: 100
Intrauterine adhesions following miscarriage
19% ( evac 16 - 18%)
Vaginal surgery for prolapse damage to bladder
2: 1000
Vaginal surgery for prolapse damage to bowel
5: 1000
Damage to bladder or ureter at TAH
7: 1000
Bowel 4: 10 000
TAH haemorrage
TAH return to theatre
23: 1000
7: 1000
COHORT
Group sharing common characteristics
For PROGNOSIS study
Followed over time to see how many will develop the outcome
CROSS-SECTIONAL
Diagnostic tests
Characteristics of a population / sample observed at a point in time
CASE-CONTROL
Studies association of disease compared with past exposure
Fetal genotyping for red cell antibodies
16/40 for all except k - 20 weeks
When to refer to FMU with antibody titres - D, C, K
D - > 4iu
C - > 7.5iu
K - Any level
TTTS affects ? of MC pregnancies
15%
Tx anaphylaxis
500mcg , 0.5ml of 1: 1000 adrenaline IM
Breech pregnancy rate
3=4%
Recurrence of breech in future pregnancy
10%
Spontaneously revert to cephalic after 36/40
3-7%
Infectious period of VZV
INCUBATION 1-3 Weeks, infectious 48 hours before rash and until lesions crusted over.
Prevelence of primary chicken pox in pregnancy
3: 1000
Chemotherapy in breast cancer
Anthracyclines - Doxorubicin , Epirubicin
Agents in breast cancer associated with gonadal toxicity
Alkylating agents - cyclophosphamide
VWD
Chromosome 12 Type 1+2 Autosomal dominant Type 3 autosomal recessive Associated with a prolonged APTT vWF AND FACTOR VIII should be checked pre invasive procedure. VIII >50 secondary PPH 25%
encapsulated bacteria
neisseria meningitis, strep pneumoniae, h. influenzae B
Normal NT thickness
<3.5mm
High risk screening
1: 150
Antenatal appointments
Nullip 10
Multip 7
PET RF
BMI > 30 FH PET Px PIH / PET PRIMIP >10 YEARS SINCE LAST DELIVERY AGE >40 MULTIPLE PREG Pre-existing vascular disease / renal disease
Labour pains
T10 - L1 inferior hypogastric plexus
Placental abrution recurrence
4.4% - 1 preg
19 - 25% - 2 preg
Emergent bleed with placenta praevia
35 - 4.7%
36 - 15%
37 - 30%
38 - 59%
vasa praevia
1: 1200-5000
Fetal mortality 60%
A vessel running in the free placental membranes within 2cm of the cervix
VTE in pregnancy
1: 1000
Risk is 4-6 times greater in pregnancy
5 x greater risk post-natal than antenatal
Recurrent VTE in preg
2-11 %
Conditions requiring higher doses of LMWH
VTE and antithrombin deficiency
VTE associated with APS
VTE recurrently
Placenta acreta in placenta praevia with previous LSCS
1 LSCS - 11-14%
2 LSCS - 23-40%
UPTO 67 with >5
Risk of death - diagnostic lap
3-8 : 100, 000